Page 108 - Read Online

Page 10 of 12 Yang et al. Mini-invasive Surg 2021;5:11 I http://dx.doi.org/10.20517/2574-1225.2021.06

Further work in prospective, multicenter, long-term follow-up designed studies is warranted to support
RYGB as an effective, long-lasting treatment option in both morbidly and non-morbidly obese Chinese
patients with T2DM.

In conclusion, This study supplements the evidence showing that RYGB is an important surgical option
for the control of obesity and weight-related T2DM in Chinese patients. Half of the patients with insulin
requirements at the time of RYGB can expect to maintain glycemic control with non-insulin AHAs after
RYGB. Those not taking insulin prior to RYGB can expect to achieve glycemic control with fewer AHAs,
and, if a patient has a short T2DM duration, glycemic control can even be achieved without the need for
AHAs.

DECLARATIONS
Acknowledgments
Funding for this study has been provided by Ethicon Endo-Surgery, Inc.

Authors’ contributions
Execution, data collection and interpretation, manuscript preparation, and final approval: Yang W
Execution, data collection, and manuscript review and final approval: Zhu S, Cheng Z, Zhang N, Wu L,
Chen Y, Yang J, Yu S
Clinical study design, data interpretation, and manuscript review and final approval: Yang TF, Ding D
Clinical study design, data interpretation, manuscript preparation, and final approval: Waggoner JR
Clinical study design, data interpretation, manuscript review and final approval: Schwiers ML, Fegelman EJ
Execution, data collection and interpretation, and manuscript review and final approval: Wang CC

Availability of data and materials
Not applicable.

Financial support and sponsorship
Funding for this study has been provided by Ethicon Endo-Surgery, Inc.

Conflicts of interest
Yang W, Zhu S, Cheng Z, Zhang N, Wu L, Chen L, Yang J, Yu S, Wang CC declare that they have no conflict
of interest. Yang TF and Ding D are employed by Johnson & Johnson Medical (Shanghai) LTD. Waggoner
JR, Schwiers ML and Fegelman EJ are employed by Ethicon Endo-Surgery, Inc.

Ethical approval and consent to participate
This study was approved by the Ethical Committee of the First Affiliated Hospital of Jinan University,
Guangzhou, China. It also was registered on the Chinese Clinical Trial Registry website (www.chictr.org.
cn) with Registration Number: ChiCTR-OOC-15006387.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. World Health Organization [Internet]. Global report on diabetes; 2016. Available from:http://apps.who.int/iris/bitstre
am/10665/204871/1/9789241565257_eng.pdf?ua=1&ua=1 [Last accessed on 26 Feb 2021]